One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome

Back to Search
Print
Bookmark Trial

NCT01113541

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Foothills Medical Centre, Department of Psychiatry
Calgary, Alberta, T2N 2T9, Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bipolar Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject must present at least 2 of the following risk factors of MS at screening: Elevated waist circumference: >102 cm in men and >88 cm in women; Elevated triglycerides (TGs): ≥1.7 mmol/L (≥150 mg/dL); Reduced HDL-Cholesterol: <1.03 mmol/L (<40 mg/dL) in men and <1.3 mmol/L (<50 mg/dL) in women; Elevated fasting glucose: ≥ 5.6 mmol/L.

- According to the clinical judgment of the investigator, the risk factors for MS have developed in close temporal relationship to starting an antipsychotic medication.

- Substitution to a less metabolically disruptive antipsychotic medication is considered

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with contraindication(s) to the use of Ziprasidone according to Canadian
prescribing information.


- Subjects with a history of treatment resistance.


- Subjects with any medical condition (e.g. pre-existing diabetes, pre-existing
dyslipidemia, thyroid pathology) or taking any concomitant medication (e.g. topiramate
or other weight loss-promoting agents, hypoglycemic agents, hypolipemic agents), that
may confound the evaluation of the study drug.


- Body mass index ≥ 40 at baseline.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Bipolar DisorderSafety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) NCT00265330
  1. Scottsdale, Arizona
  2. San Diego, California
  3. Aurora, Colorado
  4. Altamonte Springs, Florida
  5. Ft. Lauderdale, Florida
  6. North Miami, Florida
  7. Orange City, Florida
  8. Tavares, Florida
  9. Decatur, Georgia
  10. Honolulu, Hawaii
  11. Terre Haute, Indiana
  12. Lexington, Kentucky
  13. Owensboro, Kentucky
  14. Shreveport, Louisiana
  15. Clinton Township, Michigan
  16. Meridian, Mississippi
  17. St. Louis, Missouri
  18. Lincoln, Nebraska
  19. Omaha, Nebraska
  20. Albuquerque, New Mexico
  21. Rochester, New York
  22. Cincinnati, Ohio
  23. Cincinnati, Ohio
  24. Cincinnati, Ohio
  25. Cleveland, Ohio
  26. Columbus, Ohio
  27. Oklahoma City, Oklahoma
  28. Oklahoma City, Oklahoma
  29. Oklahoma City, Oklahoma
  30. Oklahoma City, Oklahoma
  31. Tulsa, Oklahoma
  32. Charleston, South Carolina
  33. Arlington, Texas
  34. DeSoto, Texas
  35. Lake Jackson, Texas
  36. Plano, Texas
  37. San Antonio, Texas
  38. Kirkland, Washington
  39. Spokane, Washington
  40. Milwaukee, Wisconsin
  41. West Allis, Wisconsin
ALL GENDERS
10 Years+
years
MULTIPLE SITES
Bipolar DisorderStudy Evaluating Bifeprunox in Bipolar Depression NCT00134459
  1. Birmingham, Alabama
  2. Beverly Hills, California
  3. National City, California
  4. Stanford, California
  5. Farmington Hills, Connecticut
  6. Bradenton, Florida
  7. Jacksonville, Florida
  8. Orlando, Florida
  9. West Palm Beach, Florida
  10. Smyrna, Georgia
  11. Honolulu, Hawaii
  12. Terre Haute, Indiana
  13. Florence, Kentucky
  14. New Orleans, Louisiana
  15. Rockville, Maryland
  16. Boston, Massachusetts
  17. Farmington Hills, Michigan
  18. St Charles, Missouri
  19. Clementon, New Jersey
  20. Moorestown, New Jersey
  21. Bronx, New York
  22. Lawrence, New York
  23. New York, New York
  24. New York, New York
  25. Staten Island, New York
  26. Winston-Salem, North Carolina
  27. Cincinnati, Ohio
  28. Dayton, Ohio
  29. Lyndhurst, Ohio
  30. Oklahoma City, Oklahoma
  31. Tulsa, Oklahoma
  32. Portland, Oregon
  33. Philadelphia, Pennsylvania
  34. Charleston, South Carolina
  35. Austin, Texas
  36. Dallas, Texas
  37. Salt Lake City, Utah
  38. Bellevue, Washington
  39. Seattle, Washington
  40. Brown Deer, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Bipolar DisorderOne-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome NCT01113541
  1. Calgary, Alberta
  2. Calgary, Alberta
  3. Penticton, British Columbia
  4. Winnipeg, Manitoba
  5. Winnipeg, Manitoba
  6. Halifax, Nova Scotia
  7. Sydney, Nova Scotia
  8. Montreal, Quebec
  9. Montreal, Quebec
  10. Sherbrooke, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Bipolar DisorderA Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression NCT00141271
  1. Birmingham, Alabama
  2. Dana Point, California
  3. La Mesa, California
  4. Laguna Hills, California
  5. Oceanside, California
  6. Orange, California
  7. San Diego, California
  8. San Diego, California
  9. Santa Ana, California
  10. Torrance, California
  11. Ft, Lauderdale, Florida
  12. Ft. Lauderdale, Florida
  13. Gainesville, Florida
  14. Hialeah, Florida
  15. Jacksonville, Florida
  16. North Miami, Florida
  17. Orlando, Florida
  18. Winter Park, Florida
  19. Atlanta, Georgia
  20. Maywood, Illinois
  21. Naperville, Illinois
  22. Schaumburg, Illinois
  23. Greenwood, Indiana
  24. Lafayette, Indiana
  25. Prarie Village, Kansas
  26. New Orleans, Louisiana
  27. Shreveport, Louisiana
  28. Shreveport, Louisiana
  29. Boston, Massachusetts
  30. Worcester, Massachusetts
  31. Minneapolis, Minnesota
  32. Flowood, Mississippi
  33. St. Louis, Missouri
  34. St. Louis, Missouri
  35. Omaha, Nebraska
  36. Las Vegas, Nevada
  37. Clementon, New Jersey
  38. Toms River, New Jersey
  39. New York, New York
  40. Staten Island, New York
  41. Cincinnati, Ohio
  42. Cleveland, Ohio
  43. Cleveland, Ohio
  44. Mayfield Village, Ohio
  45. Oklahoma City, Oklahoma
  46. Philadelphia, Pennsylvania
  47. Philadelphia, Pennsylvania
  48. Pittsburgh, Pennsylvania
  49. Charleston, South Carolina
  50. Columbia, South Carolina
  51. Memphis, Tennessee
  52. Nashville, Tennessee
  53. Bellaire, Texas
  54. Dallas, Texas
  55. Dallas, Texas
  56. DeSoto, Texas
  57. Galveston, Texas
  58. Houston, Texas
  59. Irving, Texas
  60. Plano, Texas
  61. Richardson, Texas
  62. San Antonio, Texas
  63. San Antonio, Texas
  64. Wichita Falls, Texas
  65. Arlington, Virginia
  66. Falls Church, Virginia
  67. Richmond, Virginia
  68. Richmond, Virginia
  69. Virginia Beach, Virginia
  70. Kirkland, Washington
  71. Milwaukee, Wisconsin
  72. Milwaukee, Wisconsin
  73. West Allis, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome
Official Title  ICMJE A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar Disorder
Brief Summary The purpose of this study is to explore the impact of Ziprasidone HCl on the distribution of metabolic syndrome (MS) risk factors in a population of Bipolar patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.
Detailed Description The trial was terminated prematurely on December 14, 2010, due to inability to recruit the planned number of subjects and shifting organizational priorities. The decision to terminate the trial was not based on any safety or efficacy concerns.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Bipolar Disorder
Intervention  ICMJE Drug: Ziprasidone HCL (oral)
Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
Other Name: Zeldox, Geodon
Study Arms  ICMJE Experimental: Active treatment (switch to oral Ziprasidone)
Intervention: Drug: Ziprasidone HCL (oral)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: March 3, 2011)		13
Original Estimated Enrollment  ICMJE
 (submitted: April 28, 2010)		155
Actual Study Completion Date  ICMJE February 2011
Actual Primary Completion Date February 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject must present at least 2 of the following risk factors of MS at screening: Elevated waist circumference: >102 cm in men and >88 cm in women; Elevated triglycerides (TGs): ?1.7 mmol/L (?150 mg/dL); Reduced HDL-Cholesterol: <1.03 mmol/L (<40 mg/dL) in men and <1.3 mmol/L (<50 mg/dL) in women; Elevated fasting glucose: ? 5.6 mmol/L.
  • According to the clinical judgment of the investigator, the risk factors for MS have developed in close temporal relationship to starting an antipsychotic medication.
  • Substitution to a less metabolically disruptive antipsychotic medication is considered

Exclusion Criteria:

  • Subjects with contraindication(s) to the use of Ziprasidone according to Canadian prescribing information.
  • Subjects with a history of treatment resistance.
  • Subjects with any medical condition (e.g. pre-existing diabetes, pre-existing dyslipidemia, thyroid pathology) or taking any concomitant medication (e.g. topiramate or other weight loss-promoting agents, hypoglycemic agents, hypolipemic agents), that may confound the evaluation of the study drug.
  • Body mass index ? 40 at baseline.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01113541
Other Study ID Numbers  ICMJE A1281190
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP